Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06878976 | Open-Label Safety Study of Solriamfetol in Subjects With Binge Eating Disorder | PHASE3 | ENROLLING BY_INVITATION | 300 | — | — | Feb 20, 2025 | Dec 1, 2026 | Nov 25, 2025 | 31 | United States |
| NCT06413433 | Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol | PHASE3 | RECRUITING | 450 | — | — | Apr 26, 2024 | Dec 1, 2025 | Nov 21, 2025 | 45 | United States |
Incidence of treatment-emergent adverse events following dosing with solriamfetol
| Arm | Type | Description |
|---|---|---|
| Solriamfetol | EXPERIMENTAL | Up to 52 weeks. |
| Solriamfetol 150 mg | EXPERIMENTAL | Up to 12 weeks |
| Solriamfetol 300 mg | EXPERIMENTAL | Up to 12 weeks |
| Placebo | PLACEBO_COMPARATOR | Up to 12 weeks |
| Name | Type | Description |
|---|---|---|
| Solriamfetol 75mg, 150 mg, or 300 mg | DRUG | Taken once daily. |
| Solriamfetol 150 mg | DRUG | Solriamfetol tablets, taken once daily |
| Solriamfetol 300 mg | DRUG | Solriamfetol tablets, taken once daily |
| Placebo | DRUG | Placebo tablets, taken once daily |
Inclusion Criteria: * Completion of the treatment period in Study SOL-BED-301. * Able to comply with study procedures. Exclusion Criteria: * Significant change in vital signs, medical history or concomitant medications since enrolling in the SOL-BED-301 study which, in the opinion of the Investig...